Agios Pharmaceuticals, Inc. - AGIO Total Company Value-to-Revenue Ratio

Public company logo of agios.com (AGIO)

Agios Pharmaceuticals management has pivoted its strategy toward rare genetic pathologies, divesting its oncology business to fund research and development. The GURU.Markets portal displays the EV/Sales multiple, where 7928.50 shows the current value of the metric. Revenues rely on sales of an anemia drug, creating a cash generator. However, high dependence on a narrow portfolio and pricing regulation in the US create certain risks.

AGIO Agios Pharmaceuticals: Enterprise Value-to-Revenue Ratio in the range 11/23/2025 - 11/20/2026

Agios - analytical breakdowns and key metrics (AGIO)

Fundamental company valuation:AGIO (agios.com)
Mass-produced product of Agios Pharmaceuticals, Inc.

This indicator compares the total enterprise value, adjusted for net debt, against annual sales to determine the asset's market premium. By analyzing the EV/Revenue multiple, an investor can see how the patents of Agios Pharmaceuticals (AGIO) in the field of rare genetic diseases allow the market to value the company with a high multiple premium due to the absence of direct competition.

Competitor analysis

ASND: Enterprise Value-to-Revenue Ratio|MDGL: EV/Sales Multiple|CORT - Total Company Value-to-Revenue Ratio|Enterprise Value-to-Revenue Ratio Rhythm Corp|Akero Corp (AKRO) - Total Company Value-to-Revenue Ratio|Enterprise Value-to-Revenue Ratio metsera.com (MTSR)|Company Value to Revenue moonlaketx.com MLTX|EV/Sales Multiple CRNX (Crinetics Pharmaceuticals, Inc.)|NAMS: Company Value to Revenue Ratio|SLNO - Enterprise Value-to-Revenue Ratio|Amicus Pharma (FOLD) - Company Value to Revenue|ETNB: EV/Sales Multiple|Structure Therapeutics Inc. - Business Value to Revenue|MDXG (MiMedx Corp) - EV/Sales Multiple|Enterprise Value-to-Revenue Multiple Rezolute Inc RZLT|EV/Sales Multiple LXRX|Total Company Value-to-Revenue Ratio MBX Corp|Altimmune Pharma - Company Value to Revenue|EV/Sales Multiple aardvarktherapeutics.com AARD|SGMT: Company Value to Revenue|Business Value to Revenue BIOA (BioAge Labs)|BMEA: EV/Sales Multiple|QNCX: Enterprise Value-to-Revenue Coefficient|GUTS (Fractyl Health, Inc.) - EV/Sales Multiple|EV/Sales Multiple vtvtherapeutics.com|Company Value to Revenue ATPC (Agape ATP Corp)|Total Company Value-to-Revenue Ratio Pluristem Therapeutics|Enterprise Value-to-Revenue Ratio synlogictx.com SYBX|LPCN: Company Value to Revenue Ratio|MTNB - Enterprise Value-to-Revenue Ratio|Spruce Biosciences, Inc. (SPRB) - Company Value to Revenue|GLTO: EV/Sales Multiple|Enterprise Value-to-Revenue Multiple Carmell Corp. (CTCX)|LUMO (Lumos Therapeutics) - EV/Sales Multiple|Organovo Corp (ONVO) - Total Company Value-to-Revenue Ratio|Enterprise Value-to-Revenue Ratio Radius Recycling (RDUS)